In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism

T. Brannan, A. Prikhojan, J. Martínez-Tica, M. D. Yahr

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Utilizing the cerebral microdialysis technique, we have compared in vivo the effects of selective MAO-A, MAO-B, and nonselective MAO inhibitors on striatal extracellular levels of dopamine (DA) and DA metabolites (DOPAC and HVA). The measurements were made in rats both under basal conditions and following L-DOPA administration. Extracellular levels of dopamine were enhanced and DA metabolite levels strongly inhibited both under basal conditions and following L-DOPA administration by pretreatment with the nonselective MAO inhibitor pargyline and the MAO-A selective inhibitors clorgyline and Ro 41-1049. The MAO-B inhibitor deprenyl had no effect on basal DA, HVA, or DOPAC levels. Nervertheless, deprenyl significantly increased DA and decreased DOPAC levels following exogenous L-DOPA administration, a finding compatible with a significant glial metabolism of DA formed from exogenous L-DOPA. We conclude that DA metabolism under basal conditions is primarily mediated by MAO-A. In contrast, both MAO-A and MAO-B mediate DA formation when L-DOPA is administered exogenously. The efficacy of newer, reversible agents which lack the "cheese effect" such as Ro 41-1049 are comparable to the irreversible MAO-A inhibitor clorgyline. The possible relevance of these findings for the treatment of Parkinson's disease is discussed.

Original languageEnglish (US)
Pages (from-to)79-89
Number of pages11
JournalJournal of Neural Transmission - Parkinson's Disease and Dementia Section
Volume10
Issue number2-3
DOIs
StatePublished - Jun 1995
Externally publishedYes

Fingerprint

Corpus Striatum
Monoamine Oxidase
Dopamine
Monoamine Oxidase Inhibitors
3,4-Dihydroxyphenylacetic Acid
Clorgyline
Selegiline
Pargyline
Basal Metabolism
Microdialysis
Cheese
Neuroglia
Parkinson Disease

Keywords

  • cerebral microdialysis
  • clorgyline
  • deprenyl
  • Dopamine
  • L-DOPA
  • MAO-A
  • MAO-B Parkinson's disease
  • monoamine oxidase
  • pargyline
  • Ro 41-1049

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism. / Brannan, T.; Prikhojan, A.; Martínez-Tica, J.; Yahr, M. D.

In: Journal of Neural Transmission - Parkinson's Disease and Dementia Section, Vol. 10, No. 2-3, 06.1995, p. 79-89.

Research output: Contribution to journalArticle

@article{1f3b1fec9ba24e7383008ce1841b24d1,
title = "In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism",
abstract = "Utilizing the cerebral microdialysis technique, we have compared in vivo the effects of selective MAO-A, MAO-B, and nonselective MAO inhibitors on striatal extracellular levels of dopamine (DA) and DA metabolites (DOPAC and HVA). The measurements were made in rats both under basal conditions and following L-DOPA administration. Extracellular levels of dopamine were enhanced and DA metabolite levels strongly inhibited both under basal conditions and following L-DOPA administration by pretreatment with the nonselective MAO inhibitor pargyline and the MAO-A selective inhibitors clorgyline and Ro 41-1049. The MAO-B inhibitor deprenyl had no effect on basal DA, HVA, or DOPAC levels. Nervertheless, deprenyl significantly increased DA and decreased DOPAC levels following exogenous L-DOPA administration, a finding compatible with a significant glial metabolism of DA formed from exogenous L-DOPA. We conclude that DA metabolism under basal conditions is primarily mediated by MAO-A. In contrast, both MAO-A and MAO-B mediate DA formation when L-DOPA is administered exogenously. The efficacy of newer, reversible agents which lack the {"}cheese effect{"} such as Ro 41-1049 are comparable to the irreversible MAO-A inhibitor clorgyline. The possible relevance of these findings for the treatment of Parkinson's disease is discussed.",
keywords = "cerebral microdialysis, clorgyline, deprenyl, Dopamine, L-DOPA, MAO-A, MAO-B Parkinson's disease, monoamine oxidase, pargyline, Ro 41-1049",
author = "T. Brannan and A. Prikhojan and J. Mart{\'i}nez-Tica and Yahr, {M. D.}",
year = "1995",
month = "6",
doi = "10.1007/BF02251224",
language = "English (US)",
volume = "10",
pages = "79--89",
journal = "Journal of Neural Transmission - Parkinson's Disease and Dementia Section",
issn = "0936-3076",
publisher = "Springer Verlag",
number = "2-3",

}

TY - JOUR

T1 - In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism

AU - Brannan, T.

AU - Prikhojan, A.

AU - Martínez-Tica, J.

AU - Yahr, M. D.

PY - 1995/6

Y1 - 1995/6

N2 - Utilizing the cerebral microdialysis technique, we have compared in vivo the effects of selective MAO-A, MAO-B, and nonselective MAO inhibitors on striatal extracellular levels of dopamine (DA) and DA metabolites (DOPAC and HVA). The measurements were made in rats both under basal conditions and following L-DOPA administration. Extracellular levels of dopamine were enhanced and DA metabolite levels strongly inhibited both under basal conditions and following L-DOPA administration by pretreatment with the nonselective MAO inhibitor pargyline and the MAO-A selective inhibitors clorgyline and Ro 41-1049. The MAO-B inhibitor deprenyl had no effect on basal DA, HVA, or DOPAC levels. Nervertheless, deprenyl significantly increased DA and decreased DOPAC levels following exogenous L-DOPA administration, a finding compatible with a significant glial metabolism of DA formed from exogenous L-DOPA. We conclude that DA metabolism under basal conditions is primarily mediated by MAO-A. In contrast, both MAO-A and MAO-B mediate DA formation when L-DOPA is administered exogenously. The efficacy of newer, reversible agents which lack the "cheese effect" such as Ro 41-1049 are comparable to the irreversible MAO-A inhibitor clorgyline. The possible relevance of these findings for the treatment of Parkinson's disease is discussed.

AB - Utilizing the cerebral microdialysis technique, we have compared in vivo the effects of selective MAO-A, MAO-B, and nonselective MAO inhibitors on striatal extracellular levels of dopamine (DA) and DA metabolites (DOPAC and HVA). The measurements were made in rats both under basal conditions and following L-DOPA administration. Extracellular levels of dopamine were enhanced and DA metabolite levels strongly inhibited both under basal conditions and following L-DOPA administration by pretreatment with the nonselective MAO inhibitor pargyline and the MAO-A selective inhibitors clorgyline and Ro 41-1049. The MAO-B inhibitor deprenyl had no effect on basal DA, HVA, or DOPAC levels. Nervertheless, deprenyl significantly increased DA and decreased DOPAC levels following exogenous L-DOPA administration, a finding compatible with a significant glial metabolism of DA formed from exogenous L-DOPA. We conclude that DA metabolism under basal conditions is primarily mediated by MAO-A. In contrast, both MAO-A and MAO-B mediate DA formation when L-DOPA is administered exogenously. The efficacy of newer, reversible agents which lack the "cheese effect" such as Ro 41-1049 are comparable to the irreversible MAO-A inhibitor clorgyline. The possible relevance of these findings for the treatment of Parkinson's disease is discussed.

KW - cerebral microdialysis

KW - clorgyline

KW - deprenyl

KW - Dopamine

KW - L-DOPA

KW - MAO-A

KW - MAO-B Parkinson's disease

KW - monoamine oxidase

KW - pargyline

KW - Ro 41-1049

UR - http://www.scopus.com/inward/record.url?scp=0029591972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029591972&partnerID=8YFLogxK

U2 - 10.1007/BF02251224

DO - 10.1007/BF02251224

M3 - Article

VL - 10

SP - 79

EP - 89

JO - Journal of Neural Transmission - Parkinson's Disease and Dementia Section

JF - Journal of Neural Transmission - Parkinson's Disease and Dementia Section

SN - 0936-3076

IS - 2-3

ER -